Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 4

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT03244982Phase 4Suspended

Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein

Role: lead

NCT01428388Not ApplicableCompleted

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Role: collaborator

NCT01393132Phase 2Completed

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

Role: collaborator

NCT00618644Not ApplicableWithdrawn

Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Role: lead

All 4 trials loaded